Outcomes of patients with metastatic neuroendocrine lung neoplasms: typical versus atypical carcinoids
Introduction: Well-differentiated neuroendocrine pulmonary tumours (NETp) are morphologically classified as typical carcinoid (TC) and atypical carcinoid (AC). There are limited data on systemic treatment for metastatic disease. Objective: Our study evaluated the median progression-free survival of...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia
2021-10-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | http://www.brazilianjournalofoncology.com.br/details/135/en-US/outcomes-of-patients-with-metastatic-neuroendocrine-lung-neoplasms--typical-versus-atypical-carcinoids |
| _version_ | 1827807023249489920 |
|---|---|
| author | Hugo Tanaka Marcelo Petrocchi Corassa Helano Freitas Milton Barros Rachel Riechelmann |
| author_facet | Hugo Tanaka Marcelo Petrocchi Corassa Helano Freitas Milton Barros Rachel Riechelmann |
| author_sort | Hugo Tanaka |
| collection | DOAJ |
| description | Introduction: Well-differentiated neuroendocrine pulmonary tumours (NETp) are morphologically classified as typical carcinoid (TC) and atypical carcinoid (AC). There are limited data on systemic treatment for metastatic disease. Objective: Our study evaluated the median progression-free survival of patients with metastatic tumours, comparing TC and AC status for different treatments.
Methods: Retrospective series of patients with metastatic NETp treated from 2002 to 2019 in a large cancer centre were analysed. Our primary endpoint was progression-free survival according to morphological classification (TC vs. AC). All patients received at least one treatment modality (e.g., somatostatin analogue [SSA], chemotherapy [ChP], and everolimus [Eve]). Variables were analysed using the chi-square test, median progression-free survival (mPFS) rates (months), with comparisons evaluated by the log-rank test.
Results: Twenty-seven patients were included: 44% with TC and 56% with AC. TC patients were on average 58-years-old, 83.3% were female, and 33.3% received more than one treatment. AC patients were on average 61-years-old, 66.7% were female, and 20% received more than one treatment. All patients were treated more frequently with SSA (TC: 75% vs. AC: 80%, p=0.756). Cisplatin and etoposide were the most frequent ChP regimen (TC: 75% vs. AC: 30%, p=0.248). Patients with TC and AC treated with SSA had higher mPFS in months (TC mPFS SSA: 14.5, Eve: 2.50, ChP: 4.0, SSA + Eve: 4.50; AC mPFS SSA: 7.50, Eve: 4.50, ChP: 7.50, SSA + Eve: 7.00).
Conclusion: Although the statistical analyses did not show a significant difference between treatment, numerically, more patients with TC or AC experienced tumor control with SSAs, where the mPFS pairs showed a possible tendency to differentiate themselves from the other regimes (Eve and ChP). |
| first_indexed | 2024-03-11T21:51:06Z |
| format | Article |
| id | doaj.art-14d39abe1d1c4cb4ab333962d7dbf32c |
| institution | Directory Open Access Journal |
| issn | 2526-8732 |
| language | English |
| last_indexed | 2024-03-11T21:51:06Z |
| publishDate | 2021-10-01 |
| publisher | Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia |
| record_format | Article |
| series | Brazilian Journal of Oncology |
| spelling | doaj.art-14d39abe1d1c4cb4ab333962d7dbf32c2023-09-26T09:00:16ZengSociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de RadioterapiaBrazilian Journal of Oncology2526-87322021-10-01170010.5935/2526-8732.20200041Outcomes of patients with metastatic neuroendocrine lung neoplasms: typical versus atypical carcinoidsHugo Tanaka0https://orcid.org/0000-0002-9513-0478Marcelo Petrocchi Corassa1https://orcid.org/0000-0002-7707-8768Helano Freitas2https://orcid.org/0000-0002-8415-073XMilton Barros3https://orcid.org/0000-0001-7916-5737Rachel Riechelmann4https://orcid.org/0000-0002-0107-9617AC Camargo Center, Department of Clinical Oncology - Sao Paulo - Sao Paulo - BrazilAC Camargo Center, Department of Clinical Oncology - Sao Paulo - Sao Paulo - BrazilAC Camargo Center, Department of Clinical Oncology - Sao Paulo - Sao Paulo - BrazilAC Camargo Center, Department of Clinical Oncology - Sao Paulo - Sao Paulo - BrazilAC Camargo Center, Department of Clinical Oncology - Sao Paulo - Sao Paulo - BrazilIntroduction: Well-differentiated neuroendocrine pulmonary tumours (NETp) are morphologically classified as typical carcinoid (TC) and atypical carcinoid (AC). There are limited data on systemic treatment for metastatic disease. Objective: Our study evaluated the median progression-free survival of patients with metastatic tumours, comparing TC and AC status for different treatments. Methods: Retrospective series of patients with metastatic NETp treated from 2002 to 2019 in a large cancer centre were analysed. Our primary endpoint was progression-free survival according to morphological classification (TC vs. AC). All patients received at least one treatment modality (e.g., somatostatin analogue [SSA], chemotherapy [ChP], and everolimus [Eve]). Variables were analysed using the chi-square test, median progression-free survival (mPFS) rates (months), with comparisons evaluated by the log-rank test. Results: Twenty-seven patients were included: 44% with TC and 56% with AC. TC patients were on average 58-years-old, 83.3% were female, and 33.3% received more than one treatment. AC patients were on average 61-years-old, 66.7% were female, and 20% received more than one treatment. All patients were treated more frequently with SSA (TC: 75% vs. AC: 80%, p=0.756). Cisplatin and etoposide were the most frequent ChP regimen (TC: 75% vs. AC: 30%, p=0.248). Patients with TC and AC treated with SSA had higher mPFS in months (TC mPFS SSA: 14.5, Eve: 2.50, ChP: 4.0, SSA + Eve: 4.50; AC mPFS SSA: 7.50, Eve: 4.50, ChP: 7.50, SSA + Eve: 7.00). Conclusion: Although the statistical analyses did not show a significant difference between treatment, numerically, more patients with TC or AC experienced tumor control with SSAs, where the mPFS pairs showed a possible tendency to differentiate themselves from the other regimes (Eve and ChP).http://www.brazilianjournalofoncology.com.br/details/135/en-US/outcomes-of-patients-with-metastatic-neuroendocrine-lung-neoplasms--typical-versus-atypical-carcinoidscarcinoid tumortypical carcinoidatypical carcinoideverolimussomatostatin analoguechemotherapyadjuvant/ neuroendocrine tumor |
| spellingShingle | Hugo Tanaka Marcelo Petrocchi Corassa Helano Freitas Milton Barros Rachel Riechelmann Outcomes of patients with metastatic neuroendocrine lung neoplasms: typical versus atypical carcinoids Brazilian Journal of Oncology carcinoid tumor typical carcinoid atypical carcinoid everolimus somatostatin analogue chemotherapy adjuvant/ neuroendocrine tumor |
| title | Outcomes of patients with metastatic neuroendocrine lung neoplasms: typical versus atypical carcinoids |
| title_full | Outcomes of patients with metastatic neuroendocrine lung neoplasms: typical versus atypical carcinoids |
| title_fullStr | Outcomes of patients with metastatic neuroendocrine lung neoplasms: typical versus atypical carcinoids |
| title_full_unstemmed | Outcomes of patients with metastatic neuroendocrine lung neoplasms: typical versus atypical carcinoids |
| title_short | Outcomes of patients with metastatic neuroendocrine lung neoplasms: typical versus atypical carcinoids |
| title_sort | outcomes of patients with metastatic neuroendocrine lung neoplasms typical versus atypical carcinoids |
| topic | carcinoid tumor typical carcinoid atypical carcinoid everolimus somatostatin analogue chemotherapy adjuvant/ neuroendocrine tumor |
| url | http://www.brazilianjournalofoncology.com.br/details/135/en-US/outcomes-of-patients-with-metastatic-neuroendocrine-lung-neoplasms--typical-versus-atypical-carcinoids |
| work_keys_str_mv | AT hugotanaka outcomesofpatientswithmetastaticneuroendocrinelungneoplasmstypicalversusatypicalcarcinoids AT marcelopetrocchicorassa outcomesofpatientswithmetastaticneuroendocrinelungneoplasmstypicalversusatypicalcarcinoids AT helanofreitas outcomesofpatientswithmetastaticneuroendocrinelungneoplasmstypicalversusatypicalcarcinoids AT miltonbarros outcomesofpatientswithmetastaticneuroendocrinelungneoplasmstypicalversusatypicalcarcinoids AT rachelriechelmann outcomesofpatientswithmetastaticneuroendocrinelungneoplasmstypicalversusatypicalcarcinoids |